IOVA Stock Analysis: Iovance Biotherapeutics | NASDAQ

Cell Therapy, Interleukin, Oncology, Melanoma

Total Rating 47

Safety 35

Buy Signal 1.80

Biotechnology
Industry Rotation: +8.4

Market Cap: 3.74B
Avg Turnover: 115M

Risk 3d forecast

Volatility93.5%

VaR 5^th Pctl13.3%

VaR vs Median-11.7%

Reward TTM

Sharpe Ratio1.78

Rel. Str. IBD99.5

Rel. Str. Peer Group94.7

Character TTM

Beta1.218

Beta Downside1.960

Hurst Exponent0.466

Drawdowns 3y

Max DD90.50%

CAGR/Max DD0.16

CAGR/Mean DD0.24

EPS (Earnings per Share)

Last SUE: 1.29
Qual. Beats: 1

Revenue

Rev. CAGR: 900.07%
Rev. Trend: 88.0%

Last SUE: 0.89
Qual. Beats: 1

Warnings

Strong Share Dilution

Altman Z'' In Financial Distress Zone

Tailwinds

Supp Ema8

Rs Leader

Idiosyncratic Leader

Confidence

Tailwind

Pullback 52w

Seasonality 11.6 years of data

Jan -2.0% 8

Feb +1.1% 5

Mar -4.1% 52

Apr -0.3% 16

May -3.8% 8

Jun +15.9% 20

Jul +3.9% 33

Aug +0.6% 2

Sep -5.7% 26

Oct +0.6% 2

Nov +2.4% 21

Dec +6.5% 30

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: IOVA Iovance Biotherapeutics

Iovance Biotherapeutics (IOVA) is a commercial-stage biopharmaceutical company headquartered in San Carlos, California, that develops and commercializes autologous cell therapies using tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers, with a focus on metastatic melanoma. Autologous TIL therapy is a form of personalized immunotherapy in which a patients own immune cells are extracted from their tumor, expanded outside the body, and reinfused to fight cancer.

The company markets two products: Amtagvi (lifileucel), an individualized T cell therapy approved for adult patients with previously treated advanced or metastatic melanoma, and Proleukin, an interleukin-2 (IL-2) product used to support TIL therapy and indicated for metastatic melanoma and metastatic renal cell carcinoma.

Iovances broader pipeline extends lifileucel into cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC), alongside next-generation candidates including LN-145 Gen 3, IOV-4001 (gene-edited TIL therapy), IOV-2001 for hematologic cancers, and IOV-3001 to support the TIL regimen. The company maintains research and licensing partnerships with the National Institutes of Health, the National Cancer Institute, Cellectis, Novartis Pharma AG, and Boehringer Ingelheim Biopharmaceuticals.

Originally incorporated in 2007 as Lion Biotechnologies, the company rebranded to Iovance Biotherapeutics in June 2017. Listed on NASDAQ since 2010 within the small-cap health care segment, Iovance operates in the biotechnology sub-industry, a sector characterized by long development cycles, regulatory risk, and reliance on clinical trial outcomes and strategic partnerships for commercialization.

Headlines to Watch Out For

Amtagvi sales ramp drives quarterly revenue growth
Lifileucel label expansion into NSCLC and cervical cancer
Cash burn raises dilution risk as operating losses persist

Piotroski VR-10 (Strict) 1.0

Net Income: -289.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.32 > 0.02 and ΔFCF/TA 3.28 > 1.0
NWC/Revenue: 110.0% < 20% (prev 121.5%; Δ -11.47% < -1%)
CFO/TA -0.29 > 3% & CFO -264.2m > Net Income -289.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.35 > 1.5 & < 3
Outstanding Shares: last quarter (450.2m) vs 12m ago 34.58% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 35.65% > 50% (prev 26.62%; Δ 9.04% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)

Altman Z'' -5.63

A: 0.39 (Total Current Assets 464.3m - Total Current Liabilities 106.8m) / Total Assets 915.5m
B: -3.17 (Retained Earnings -2.90b / Total Assets 915.5m)
C: -0.32 (EBIT TTM -293.8m / Avg Total Assets 911.5m)
D: 4.10 (Book Value of Equity 736.0m / Total Liabilities 179.5m)
Altman-Z'' = -5.63 = D

Beneish M -3.35

DSRI: 1.27 (Receivables 102.1m/59.9m, Revenue 325.0m/241.5m)
GMI: 0.21 (GM 20.60% / 97.76%)
AQI: 0.88 (AQ_t 0.30 / AQ_t-1 0.34)
SGI: 1.35 (Revenue 325.0m / 241.5m)
TATA: -0.03 (NI -289.5m - CFO -264.2m) / TA 915.5m)
Beneish M = -3.35 (Cap -4..+1) = AA

What is the price of IOVA shares?

As of September 03, 2026, the stock is trading at USD 8.62 with a total of 12,296,857 shares traded. Over the past week, the price has changed by +6.68%, over one month by +99.54%, over three months by +110.24% and over the past year by +293.61%.

Current recommended Stop Loss: 8.00 (which is 7.2% or 1.1 ATR below the current price).

Is IOVA a buy, sell or hold?

Iovance Biotherapeutics has received a consensus analysts rating of 4.08. Therefore, it is recommended to buy IOVA.

StrongBuy: 5
Buy: 3
Hold: 4
Sell: 0
StrongSell: 0

What are the forecasts/targets for the IOVA price?

Analysts Target Price	10	16%

Iovance Biotherapeutics (IOVA) - Fundamental Data Overview as of 29 August 2026

Market Cap USD = 3.74b (3.74b USD * 1.0 USD.USD)
P/S = 11.5135
P/B = 5.0626
Revenue TTM = 325.0m USD
EBIT TTM = -293.8m USD
EBITDA TTM = -262.8m USD
Long Term Debt = 43.3m USD (estimated: total debt 46.0m - short term 2.67m)
Short Term Debt = 2.67m USD (from shortTermDebt, last quarter)
Debt = 46.0m USD (from shortLongTermDebtTotal, last quarter) (leases 46.0m already included)
Net Debt = -251.7m USD (calculated: Debt 46.0m - CCE 297.7m)
Enterprise Value = 3.49b USD (3.74b + Debt 46.0m - CCE 297.7m)
Interest Coverage Ratio = unknown (Ebit TTM -293.8m / Interest Expense TTM 0.0)
EV/FCF = -11.77x (Enterprise Value 3.49b / FCF TTM -296.4m)
FCF Yield = -8.49% (FCF TTM -296.4m / Enterprise Value 3.49b)
FCF Margin = -91.21% (FCF TTM -296.4m / Revenue TTM 325.0m)
Net Margin = -89.09% (Net Income TTM -289.5m / Revenue TTM 325.0m)
Gross Margin = unknown ((Revenue TTM 325.0m - Cost of Revenue TTM 7.29m) / Revenue TTM)
Tobins Q-Ratio = 3.81 (Enterprise Value 3.49b / Total Assets 915.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 46.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -232.1m (EBIT -293.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.35 (Total Current Assets 464.3m / Total Current Liabilities 106.8m)
Debt / Equity = 0.06 (Debt 46.0m / totalStockholderEquity, last quarter 736.0m)
Debt / EBITDA = 0.96 (negative EBITDA) (Net Debt -251.7m / EBITDA -262.8m)
Debt / FCF = 0.85 (negative FCF - burning cash) (Net Debt -251.7m / FCF TTM -296.4m)
Total Stockholder Equity = 714.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.76% (Net Income -289.5m / Total Assets 915.5m)
RoE = -40.51% (Net Income TTM -289.5m / Total Stockholder Equity 714.7m)
RoCE = -38.76% (EBIT -293.8m / Capital Employed (Equity 714.7m + L.T.Debt 43.3m))
RoIC = -29.19% (negative operating profit) (NOPAT -232.1m / Invested Capital 795.1m)
WACC = 10.15% (E(3.74b)/V(3.79b) * Re(10.27%) + D(46.0m)/V(3.79b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.27% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.85 | Cagr: 26.30%
[DCF] Fair Price = unknown (Cash Flow -296.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.29 | # QB: 1
Revenue Correlation: 87.98 | Revenue CAGR: 900.1% | SUE: 0.89 | # QB: 1
EPS current Quarter (2026-09-30): EPS=-0.10 | Chg30d=+22.25% | Revisions=+57% | Analysts=7
EPS current Year (2026-12-31): EPS=-0.50 | Chg30d=+12.08% | Revisions=+57% | GrowthEPS=+54.5% | GrowthRev=+52.4%
EPS next Year (2027-12-31): EPS=-0.29 | Chg30d=+10.58% | Revisions=+38% | GrowthEPS=+42.0% | GrowthRev=+38.8%
[Analyst] Revisions Ratio: +69% (up=12, down=1)